Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRV043
MIFTS: 41

Cervical Dystonia

Categories: Rare diseases, Neuronal diseases, Muscle diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Cervical Dystonia

About this section

MalaCards integrated aliases for Cervical Dystonia:

Name: Cervical Dystonia 12 53 37 15
Spasmodic Torticollis 12 76 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0050840
KEGG 37 H01608
ICD10 33 G24.3
Sources

Summaries for Cervical Dystonia

About this section
NIH Rare Diseases : 53 Cervical dystoniais a neurological condition characterized by excessive pulling of the muscles of the neck and shoulder resulting in abnormal movements of the head (dystonia). Most commonly, the head turns to one side or the other. Tilting sideways, or to the back or front may also occur. The turning or tilting movements may be accompanied by shaking movement (tremor) and/or soreness of the muscles of the neck and shoulders. Cervical dystonia can occur at any age, but most cases occur in middle age. It often begins slowly and usually reaches a plateau over a few months or years. The cause of cervical dystonia is often unknown. In some cases there is a family history. Several genes have been associated with cervical dystonia, including GNAL, THAP1, CIZ1, and ANO3. Other cases may be linked to an underlying disease (e.g. Parkinson disease), neck trauma, or certain medications. Treatment may include local injections of botulinum toxin, pain medications, benzodiazepines (anti-anxiety medications), anticholinergics, physical therapy, or surgery.

MalaCards based summary : Cervical Dystonia, also known as spasmodic torticollis, is related to dystonia 24 and torticollis. An important gene associated with Cervical Dystonia is CIZ1 (CDKN1A Interacting Zinc Finger Protein 1). The drugs Acetylcholine and Menthol have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and testes, and related phenotypes are behavior/neurological and mortality/aging

Disease Ontology : 12 A focal dystonia that is characterized by simultaneous contraction of the agonist and antagonist muscles that control the position of the head contracting during dystonic movement which causes the neck to involuntarily turn to the left, right, upwards, and/or downwards.

Wikipedia : 76 Spasmodic torticollis is an extremely painful chronic neurological movement disorder causing the neck to... more...

Sources

Related Diseases for Cervical Dystonia

About this section

Diseases related to Cervical Dystonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 dystonia 24 31.5 THAP1 TOR1A
2 torticollis 30.8 CIZ1 TOR1A
3 dystonia 11, myoclonic 30.0 CAMP GCH1 THAP1 TOR1A
4 spasmodic dysphonia 29.9 THAP1 TOR1A
5 substance abuse 29.2 BDNF DRD5
6 dystonia 29.1 CIZ1 DRD5 GCH1 GNAL THAP1 TOR1A
7 focal hand dystonia 28.1 CAMP DRD5 THAP1 TOR1A
8 spasmodic dystonia 27.9 CAMP GNAL THAP1 TOR1A
9 blepharospasm 27.5 CAMP DRD5 GCH1 GNAL THAP1 TOR1A
10 lymphedema, hereditary, ii 27.2 CAMP DRD5 GCH1 THAP1 TOR1A
11 focal dystonia 25.6 CAMP CDIP1 CIZ1 DRD5 GNAL THAP1
12 dystonia 23 11.6
13 torticollis, familial 11.5
14 leukoencephalopathy with dystonia and motor neuropathy 11.3
15 x-linked dystonia-parkinsonism/lubag 11.1
16 cervicitis 11.1
17 dystonia 4, torsion, autosomal dominant 10.9
18 dystonia 7, torsion 10.9
19 torsion dystonia 4 10.9
20 adolescent-onset dystonia of mixed type 10.9
21 tremor 10.3
22 essential tremor 10.1
23 autosomal dominant cerebellar ataxia 10.0
24 autoimmune disease of gastrointestinal tract 10.0 HLA-DQA1 TOR1A
25 cerebritis 10.0
26 headache 10.0
27 multifocal dystonia 10.0 CAMP TOR1A
28 thiamine metabolism dysfunction syndrome 2 10.0 GCH1 TOR1A
29 aging 10.0
30 laryngitis 10.0
31 dysphagia 10.0
32 hemifacial spasm 10.0
33 brachial plexus lesion 9.9 BDNF CAMP
34 spinocerebellar ataxia 2 9.9
35 acute cervicitis 9.9
36 movement disease 9.9
37 spasticity 9.9
38 dystonia 3, torsion, x-linked 9.9 GCH1 THAP1
39 myasthenia gravis 9.8
40 aceruloplasminemia 9.8
41 ataxia-oculomotor apraxia 3 9.8
42 cerebral palsy 9.8
43 dyskinetic cerebral palsy 9.8
44 scoliosis 9.8
45 dementia 9.8
46 ischemia 9.8
47 plexopathy 9.8
48 radiculopathy 9.8
49 congenital torticollis 9.8
50 fibromatosis 9.8

Graphical network of the top 20 diseases related to Cervical Dystonia:



Diseases related to Cervical Dystonia
Sources

Symptoms & Phenotypes for Cervical Dystonia

About this section

MGI Mouse Phenotypes related to Cervical Dystonia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.5 BDNF CIZ1 DRD5 GNAL NALCN THAP1
2 mortality/aging MP:0010768 9.23 GNAL NALCN THAP1 TOR1A BDNF CAMP
Sources

Drugs & Therapeutics for Cervical Dystonia

About this section

Drugs for Cervical Dystonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
2
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
3 abobotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
4 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
6 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Neuromuscular Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 onabotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
12 rimabotulinumtoxinB Phase 4,Phase 2
13 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
14
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
15 Antihypertensive Agents Phase 2, Phase 3
16 Vasodilator Agents Phase 2, Phase 3
17 Adrenergic Agents Phase 2, Phase 3
18 Adrenergic Antagonists Phase 2, Phase 3
19 Adrenergic beta-Antagonists Phase 2, Phase 3
20 Anti-Arrhythmia Agents Phase 2, Phase 3
21
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078
22
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
23
Amlodipine Approved Phase 2 88150-42-9 2162
24 Etiracetam Investigational Phase 2 33996-58-6
25 Analgesics Phase 2,Phase 1
26 Analgesics, Non-Narcotic Phase 2,Phase 1
27 Cannabinoid Receptor Agonists Phase 2
28 Hallucinogens Phase 2
29 Hormone Antagonists Phase 2
30 Hormones Phase 2
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
32 Psychotropic Drugs Phase 2
33 Anti-Inflammatory Agents Phase 1, Phase 2,Not Applicable
34 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
35 Antirheumatic Agents Phase 1, Phase 2
36 Autoantibodies Phase 1, Phase 2
37 Gastrointestinal Agents Phase 1, Phase 2
38 Immunosuppressive Agents Phase 1, Phase 2
39 calcium channel blockers Phase 2
40 Calcium, Dietary Phase 2
41 Anticonvulsants Phase 2
42 Nootropic Agents Phase 2
43
Trihexyphenidyl Approved 58947-95-8, 144-11-6 5572
44
Triamcinolone Approved, Vet_approved Not Applicable 124-94-7 31307
45
Cortisone acetate Approved, Investigational Not Applicable 1950-04-4, 50-04-4 5745
46
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
47
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
48 Antiparkinson Agents
49 Cholinergic Antagonists
50 Muscarinic Antagonists

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
2 Botox for Cervical Dystonia Following EMG Mapping Completed NCT00773253 Phase 4 Botulinum toxin A
3 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
4 An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia Completed NCT00702754 Phase 4
5 Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex Completed NCT01486264 Phase 4
6 Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia Completed NCT00541905 Phase 4 NT 201
7 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
8 Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
9 Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia Completed NCT01384214 Phase 4
10 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia Completed NCT00528541 Phase 4
11 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
12 OnabotulinumtoxinA in the Management of Psychogenic Dystonia Recruiting NCT02618889 Phase 4
13 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
14 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia Terminated NCT00432341 Phase 4
15 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
16 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Completed NCT00447772 Phase 3 Botulinum type A toxin (Dysport®)
17 Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Completed NCT01753310 Phase 3 Dysport®;Placebo
18 Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia Completed NCT01261611 Phase 3 Botulinum type A toxin (Dysport RU®);Botulinum type A toxin (Dysport®);Placebo
19 Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia Completed NCT00148889 Phase 3
20 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Completed NCT01753336 Phase 3 Dysport®
21 Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3 abobotulinumtoxinA (Dysport) 250-1000 units
22 Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00257660 Phase 3 Botulinum type A toxin (Dysport®);Placebo
23 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia Completed NCT00407030 Phase 3 incobotulinumtoxinA (Xeomin) (240 Units);incobotulinumtoxinA (Xeomin) (120 Units);Placebo
24 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
25 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
26 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
27 Meditoxin® Treatment in Patients With Cervical Dystonia Recruiting NCT03232320 Phase 3 Meditoxin;Placebo
28 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Recruiting NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
29 ASIS for Botox in Cervical Dystonia Unknown status NCT02074293 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Botox intramuscularly at Week 6;Efficacy of Botox intramuscularly at Week 12;Efficacy of Botox intramuscularly at Week 18;Efficacy of Botox intramuscularly at Week 24;Efficacy of Botox intramuscularly at Week 30;Efficacy of Botox subdermally at Week 6;Efficacy of Botox subdermally at Week 12;Efficacy of Botox subdermally at Week 18;Efficacy of Botox subdermally at Week 24;Efficacy of Botox subdermally at Week 30;Adverse Reactions of Botox intramuscularly;Adverse Reactions of Botox subdermally
30 Efficacy of Dronabinol for the Treatment of Cervical Dystonia Unknown status NCT00418925 Phase 2 Dronabinol
31 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
32 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia Completed NCT00564681 Phase 2 Normal Saline
33 Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain Completed NCT00178945 Phase 1, Phase 2 Botulinum Toxin Type A
34 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis Completed NCT00165776 Phase 2 BOTULINUM TOXIN TYPE B
35 Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia Completed NCT02706795 Phase 2
36 Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia Completed NCT01588574 Phase 2
37 Amlodipine Plus Botulinum Toxin for Focal Dystonia Completed NCT00015457 Phase 2 Amlodipine plus Botulinum toxin
38 Deep Brain Stimulation for Cervical Dystonia Completed NCT00105430 Phase 2
39 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects Completed NCT00280384 Phase 2 E2014 (Botulinum toxin type B);E2014 (Botulinum toxin type B) Placebo
40 Deep Brain Stimulation in Patients With Dystonia Completed NCT00773604 Phase 1, Phase 2
41 Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia Recruiting NCT02662530 Phase 2 Botulinum Toxin Type A
42 Safety and Tolerability of Perampanel in Cervical Dystonia Recruiting NCT02131467 Phase 1, Phase 2 Perampanel
43 Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin Recruiting NCT02867787 Phase 2 Botox arm
44 Keppra for Cervical Dystonia Suspended NCT00760318 Phase 2 Keppra
45 Botulinum Toxin Injection Efficiency Unknown status NCT01041157 Phase 1
46 PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia Completed NCT00549341 Phase 1 Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
47 Deep Brain Stimulation to Treat Cervical Dystonia Completed NCT00132340 Phase 1
48 A Multicenter Pilot Study of Pallidal Deep Brain Stimulation for Cervical Dystonia Unknown status NCT00132990 Not Applicable
49 Cerebellum and Cortical Plasticity: the Case of Dystonia Unknown status NCT01272154 Not Applicable
50 Humanitarian Device Exemption Approved for marketing NCT00580658

Search NIH Clinical Center for Cervical Dystonia

Sources

Genetic Tests for Cervical Dystonia

About this section
Sources

Anatomical Context for Cervical Dystonia

About this section

MalaCards organs/tissues related to Cervical Dystonia:

41
Brain, Cerebellum, Testes, Globus Pallidus, Cortex, Subthalamic Nucleus, T Cells
Sources

Publications for Cervical Dystonia

About this section

Articles related to Cervical Dystonia:

(show top 50) (show all 658)
# Title Authors Year
1
INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. ( 29270685 )
2018
2
Sensory Trick in a Patient with Cervical Dystonia: Insights from Magnetoencephalography. ( 29565281 )
2018
3
Pedunculopontine Nucleus Cholinergic Deficiency in Cervical Dystonia. ( 29508906 )
2018
4
Speech induced cervical dystonia: An unusual task specific dystonia. ( 29174183 )
2018
5
The effects of a relaxation program featuring aquatic therapy and autogenic training among people with cervical dystonia (a pilot study). ( 29939827 )
2018
6
A 500A U/2A mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. ( 29343142 )
2018
7
Abnormal cerebellar processing of the neck proprioceptive information drives dysfunctions in cervical dystonia. ( 29396401 )
2018
8
Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia. ( 29443021 )
2018
9
GABA<sub>A</sub> Receptor Availability Changes Underlie Symptoms in Isolated Cervical Dystonia. ( 29670567 )
2018
10
The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli. ( 29205495 )
2018
11
Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. ( 29557988 )
2018
12
Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. ( 29731634 )
2018
13
Physiological effects of subthalamic nucleus deep brain stimulation surgery in cervical dystonia. ( 29326293 )
2018
14
High prevalence of olfactory dysfunction in cervical dystonia. ( 29724603 )
2018
15
Postural control and the relation with cervical sensorimotor control in patients with idiopathic adult-onset cervical dystonia. ( 29340715 )
2018
16
The effects of a laser-guided postural reeducation program on pain, neck active range of motion, and functional improvement in a 75-year-old patient with cervical dystonia. ( 29939800 )
2018
17
Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia. ( 29173657 )
2018
18
Changes in sensorimotor network activation after botulinum toxin type A injections in patients with cervical dystonia: a functional MRI study. ( 29971454 )
2018
19
Is perception of visual verticality intact in patients with idiopathic cervical dystonia? ( 29101737 )
2018
20
Cervical dystonia and substance abuse. ( 29569175 )
2018
21
Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy. ( 29772695 )
2018
22
Cortical modulation of brainstem circuits is abnormal in cervical dystonia. ( 29704573 )
2018
23
Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo? ( 29910156 )
2018
24
Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. ( 29326295 )
2018
25
Pilot Study of a Device to Induce the Hanger Reflex in Patients with Cervical Dystonia. ( 29607887 )
2018
26
Relationships between Serotonin Transporter Binding in the Raphe Nuclei, Basal Ganglia, and Hippocampus with Clinical Symptoms in Cervical Dystonia: A [<sup>11</sup>C]DASB Positron Emission Tomography Study. ( 29541052 )
2018
27
Oropharyngeal dysphagia in adults with dyskinetic cerebral palsy and cervical dystonia: a preliminary study. ( 29958905 )
2018
28
Sertraline induced cervical dystonia in a patient of Obsessive Compulsive Disorder. ( 29447992 )
2018
29
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia. ( 29066869 )
2017
30
Endophenotyping in idiopathic adult onset cervical dystonia. ( 28511126 )
2017
31
Alterations of resting-state fMRI measurements in individuals with cervical dystonia. ( 28504361 )
2017
32
Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. ( 28239516 )
2017
33
The occurrence of lateral shift in cervical dystonia. ( 28054172 )
2017
34
Modulation of the muscle activity during sleep in cervical dystonia. ( 28525628 )
2017
35
Cervical sensorimotor control in idiopathic cervical dystonia: AA cross-sectional study. ( 28948067 )
2017
36
Reply: Contributions of visual and motor signals in cervical dystonia. ( 27993889 )
2017
37
Ultrasound imaging and guidance in the management of cervical dystonia: A caveat on the compartmentalization of sternocleidomastoid muscle. ( 28851563 )
2017
38
Measuring Disability in Patients With Cervical Dystonia According to the International Classification of Functioning, Disability and Health. ( 28621218 )
2017
39
Evaluation of the Edrophonium Challenge Test for Cervical Dystonia. ( 28824069 )
2017
40
Cortical inhibitory function in cervical dystonia. ( 29311009 )
2017
41
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? ( 28888929 )
2017
42
Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia. ( 28478527 )
2017
43
Expanding the phenotype of phosphomannomutase-2 gene congenital disorder of glycosylation: Cervical dystonia. ( 28566178 )
2017
44
Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment. ( 28832550 )
2017
45
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. ( 28891721 )
2017
46
Ixcellence NetworkAr: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. ( 28676144 )
2017
47
Biased Visuospatial Attention in Cervical Dystonia. ( 28791940 )
2017
48
The influence of occlusal stabilization appliances on cervical dystonia symptoms. ( 29151795 )
2017
49
Sensory tricks in primary blepharospasm and idiopathic cervical dystonia. ( 28488615 )
2017
50
Contributions of visual and motor signals in cervical dystonia. ( 27993890 )
2017
Sources

Variations for Cervical Dystonia

About this section
Sources

Expression for Cervical Dystonia

About this section
Search GEO for disease gene expression data for Cervical Dystonia.
Sources

Pathways for Cervical Dystonia

About this section
Sources

GO Terms for Cervical Dystonia

About this section

Biological processes related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of adenylate cyclase activity GO:0007190 9.26 DRD5 GNAL
2 negative regulation of blood pressure GO:0045776 9.16 DRD5 GCH1
3 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 8.96 DRD5 GNAL
4 regulation of protein localization to cell surface GO:2000008 8.62 BDNF TOR1A
Sources

Sources for Cervical Dystonia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....